Sep. 16 at 4:35 PM
$AIMD is showing an interesting shift from validation toward commercialization. VASRO research highlights Ainos’ AI Nose platform gaining momentum in semiconductor applications, with its front end program moving into initial commercial orders and a 2.1M back end subscription program providing an early revenue benchmark. Add in Ainos’ proprietary chemical dataset with 1B+ records and its broader Chemical Intelligence strategy, and the company has multiple potential avenues for growth as commercialization develops.
$AIMD is one to watch closely.